Novartis Adds Myfortic To Transplant Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis gained approval for Myfortic (mycophenolate sodium) Feb. 27 for use in kidney transplantation
You may also be interested in...
Novartis’ Myfortic Can Increase Risk Of Fetal Damage, FDA Finds
The finding for the organ transplant drug follows by a month a similar warning about Roche competitor, CellCept.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).